Advantages and limitations of microarray technology in human cancer

被引:192
作者
Russo, G
Zegar, C
Giordano, A
机构
[1] Temple Univ, Dept Biotechnol, Coll Sci & Technol, Sbarro Inst Canc Res & Mol Med, Philadelphia, PA 19122 USA
[2] Univ Siena, Dept Human Pathol & Oncol, I-53100 Siena, Italy
基金
美国国家卫生研究院;
关键词
microarray; proteomics; human cancer;
D O I
10.1038/sj.onc.1206865
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Cancer is a highly variable disease with multiple heterogeneous genetic and epigenetic changes. Functional studies are essential to understanding the complexity and polymorphisms of cancer. The final deciphering of the complete human genome, together with the improvement of high throughput technologies, is causing a fundamental transformation in cancer research. Microarray is a new powerful tool for studying the molecular basis of interactions on a scale that is impossible using conventional analysis. This technique makes it possible to examine the expression of thousands of genes simultaneously. This technology promises to lead to improvements in developing rational approaches to therapy as well as to improvements in cancer diagnosis and prognosis, assuring its entry into clinical practice in specialist centers and hospitals within the next few years. Predicting who will develop cancer and how this disease will behave and respond to therapy after diagnosis will be one of the potential benefits of this technology within the next decade. In this review, we highlight some of the recent developments and results in microarray technology in cancer research, discuss potentially problematic areas associated with it, describe the eventual use of microarray technology for clinical applications and comment on future trends and issues.
引用
收藏
页码:6497 / 6507
页数:11
相关论文
共 131 条
[61]   Classification and diagnostic prediction of cancers using gene expression profiling and artificial neural networks [J].
Khan, J ;
Wei, JS ;
Ringnér, M ;
Saal, LH ;
Ladanyi, M ;
Westermann, F ;
Berthold, F ;
Schwab, M ;
Antonescu, CR ;
Peterson, C ;
Meltzer, PS .
NATURE MEDICINE, 2001, 7 (06) :673-679
[62]  
Khan J, 1998, CANCER RES, V58, P5009
[63]   Osteopontin as a potential diagnostic biomarker for ovarian cancer [J].
Kim, JH ;
Skates, SJ ;
Uede, T ;
Wong, KK ;
Schorge, JO ;
Feltmate, CM ;
Berkowitz, RS ;
Cramer, DW ;
Mok, SC .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2002, 287 (13) :1671-1679
[64]  
Knezevic V, 2001, PROTEOMICS, V1, P1271, DOI 10.1002/1615-9861(200110)1:10<1271::AID-PROT1271>3.0.CO
[65]  
2-6
[66]   Protein microarrays: prospects and problems [J].
Kodadek, T .
CHEMISTRY & BIOLOGY, 2001, 8 (02) :105-115
[67]   Tissue microarrays for high-throughput molecular profiling of tumor specimens [J].
Kononen, J ;
Bubendorf, L ;
Kallioniemi, A ;
Bärlund, M ;
Schraml, P ;
Leighton, S ;
Torhorst, J ;
Mihatsch, MJ ;
Sauter, G ;
Kallioniemi, OP .
NATURE MEDICINE, 1998, 4 (07) :844-847
[68]  
Kudoh K, 2000, CANCER RES, V60, P4161
[69]   Array of hope [J].
Lander, ES .
NATURE GENETICS, 1999, 21 (Suppl 1) :3-4
[70]   Gene discovery in oral squamous cell carcinoma through the Head and Neck Cancer Genome Anatomy Project: confirmation by microarray analysis [J].
Leethanakul, C ;
Knezevic, V ;
Patel, V ;
Amornphimoltham, P ;
Gillespie, J ;
Shillitoe, EJ ;
Emko, P ;
Park, MH ;
Emmert-Buck, MR ;
Strausberg, RL ;
Krizman, DB ;
Gutkind, JS .
ORAL ONCOLOGY, 2003, 39 (03) :248-258